A National, Prospective, Randomized, Open Label Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin vs IV Ceftriaxone + IV Azithromycin Followed by PO Amoxicilline/Clavulanate and PO Clarithromycin in Subjects With Community-acquired Pneumonia

NCT00717561 Phase 3 COMPLETED

The purpose of this study is to assess if a therapy with oral and intravenous moxifloxacin is as effective as a therapy with intravenous ceftriaxone + intravenous azithromycin followed by oral amoxicilline/clavulanate and oral clarithromycin in the treatment of community-acquired pneumonia.

Details

Lead sponsor	Bayer
Phase	Phase 3
Status	COMPLETED
Enrolment	60
Start date	2008-02
Completion	2009-06

Conditions

• Pneumonia

Interventions

• Avelox (Moxifloxacin, BAY12-8039)
• Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin

Primary outcomes

• Clinical response 20 days after completion of study treatment (Test-of-Cure visit) — 20 days after last dose of study drug (TOC Visit)

Countries

Italy